Drugs / SCB-1022
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06984094 | Jun 2025 → Mar 2028 expected | parainfluenza infectious disease, respiratory syncytial virus infectious disease | Clover Biopharmaceuticals AUS Pty | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCB-1022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06984094 ↗ |
| Modality | Vaccine | “SCB-1022 (combination recombinant RSV-hMPV vaccine candidate)” NCT06984094 ↗ |